Flow Cytometry Market worth US$9.85 billion in 2033 with 8.7% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The global Flow Cytometry Market, valued at US$4.87 billion in 2024 stood at US$5.06...
DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The global Flow Cytometry Market, valued at US$4.87 billion in 2024 stood at US$5.06...
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4...
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented...
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients...
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at...
SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance...
New data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes-highlighting its potential...
Company advances development of first-in-class solid tumor immunotherapy platformLOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Tidewave Bio, a biotechnology...
The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD...
Groundbreaking study in Communications Medicine highlights AI's role in transforming immunotherapy decisions and precision oncology IRVING, Texas, Aug. 6, 2025...
MyBladderCancerTeam and MyEndometrialCancer Team connect oncology patients with medically reviewed online content and support SAN FRANCISCO, Aug. 6, 2025 /PRNewswire/...
Acquisition to Include DANYELZA® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product PortfolioTransaction Expands SERB’s Investment in the U.S.SERB to Commence...
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation...
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of...
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapiesROCKVILLE, Md., July 31,...